



Clover Corporation Limited

ABN 85 003 622 866

ASX ANNOUNCEMENT

25 September 2014

Clover achieves GRAS status for high dose DHA pre-term emulsion

Clover is very pleased to announce that its patented high dose DHA emulsion and associated delivery system has received Generally Regarded as Safe (GRAS) status for use in pre-term infants. GRAS is a status assigned by the FDA to substances not known to be hazardous to health and thus approved for use in foods.

This emulsion is the first high dose DHA enteral product permitted for use in pre-term infants.

Clover's GRAS determination was supported by the unanimous consensus of an internationally recognised panel of scientific experts in the areas of food toxicology and paediatric gastroenterology.

This successful GRAS outcome is a significant and critical milestone in Clover's medical food program. As noted in previous announcements, the Phase 3 clinical trial using the now GRAS approved high dose pre-term emulsion is progressing very well. Results of the trial are expected by June 2015.

About Clover Corporation:

Clover Corporation Limited seeks to identify, develop and commercialize functional and nutritional ingredients in the infant formula and nutraceutical market. Its wholly owned subsidiary, Nu-Mega Ingredients Pty. Ltd., is a world class manufacturer and supplier of HiDHA omega-3 tuna oil and Driphorm microencapsulated nutritionally important lipid ingredients.

Company Contacts:

Darren Callahan – Interim Chief Executive Officer +613 8347 5001

Jaime Pinto – Company Secretary +612 9210 7000